PPT-Asymptomatic plasma cell dyscrasias –Smoldering myeloma & MGUS

Aric Hall MD Assistant Professor UW Health Objectives To discuss pathophysiology of plasma cell disorders To define and describe the asymptomatic plasma cell dyscrasias To discuss prognosis. Ready for Prime Time?. DANA-FARBER . CANCER INSTITUTE. Nikhil C. Munshi, MD . Professor of Medicine . Harvard Medical School. Boston VA Healthcare System. Director . Basic and Correlative Sciences. Dana-Farber Cancer . Matthew 12:20 & Isaiah 42:3. Robert C. Newman. Introduction. In Matthew 13:52, Jesus gives us the parable of the householder bringing out things old and new:. (NIV) He said to them, "Therefore every teacher of the law who has been instructed about the kingdom of heaven is like the owner of a house who brings out of his storeroom new treasures as well as old." . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Starr Morning Report Austin Akers, MD Internal Medicine PGY-3 Patient is a 59 year old previously fit and active male in remarkably good health for his age who has experienced a rapid overall physical decline over the last 2-3 months Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. Can we do better?. [Hospital name]. [Date]. What is myeloma?. Cancer of plasma cells. Leads to:. Bone infiltration. - fractures (especially vertebral wedge fractures), hypercalcaemia. - pain. Professor Mark Drayson, University of Birmingham. 13. th. March 2019. Distinguishing myeloma from MGUS by m-protein and serum free light chain results alone. M. yeloma . is the worst cancer for delayed diagnosis . MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI Multiple Myeloma is a cancer of Plasma cell dyscrasias are diseases characterized by clonal proliferation and accumulation of cells producing monoclonal immunoglobulins. These diseases have not been studied in our region and we don Risk stratification and Therapeutic Options. Natalie S. Callander, M.D.. University of Wisconsin Carbone Cancer Center. 1. MGUS definition. 2. Factors associated with MGUS progression. 3. Appropriate evaluation.